Sun gung ho on psoriasis asset amid brodalumab setback
This article was originally published in Scrip
Amgen's decision to dump co-development and commercialization plans of the interleukin-17 inhibitor brodalumab with AstraZeneca appears to have significantly buoyed the outlook for Sun Pharma's late-stage asset for chronic plaque psoriasis, tildrakizumab.
You may also be interested in...
Sun Builds On Psoriasis Data But Can It Hold In Crowded Space?
Sun Pharma’s executive vice president, biologics and dermatology, Jesper Ostergaard Jensen, elaborates on some aspects of the recent encouraging data around the company’s late stage psoriasis asset, tildrakizumab. Jensen also tells Scrip that the firm is upbeat about its acne and photodynamic therapy products in the US.
What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.
Backed By Big Names, Etherna Hopes To Disrupt mRNA Space
Belgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.